DOJ Moves to Reclassify Medical Marijuana

What Happened?

The Department of Justice (DOJ) has taken big steps in how marijuana is treated under federal law, specifically focusing on state-licensed medical use. Acting Attorney General Todd Blanche signed an order to reclassify medical marijuana, advancing an effort to align federal policy with its growing use at the state level.

The Justice Department is pushing to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. The reclassification would place medical marijuana alongside drugs such as ketamine and prescription medication, a lower classification for abuse risk and recognized medical use.

However, the change would only apply to state-licensed medical marijuana, while other forms would still remain illegal at the federal level. Officials from the DOJ say that the goal is to further expand research with the ultimate goal of improving our understanding of marijuana’s medical effects. They have also accelerated the rulemaking process to formalize the change, an effort initiated but not seen through under the Biden administration.

Why It Matters

Reclassification changes how marijuana is treated by regulators, researchers, and medical professionals. Schedule I drugs are considered to have no accepted medical use and face strict limitations on research. Moving marijuana to Schedule III removes those barriers, making it easier to study its safety, effectiveness, and potential applications.

Google just lost a $100 billion antitrust case. Here's who benefits

A federal judge just ruled that Google illegally monopolized the online advertising market.

The DOJ wants a breakup.

If it happens, billions of dollars in digital ad spend will need somewhere new to go.

That's a problem for Google. But it's a tailwind for platforms that already sit between brands and consumers.

Platforms like Mode Mobile.

Mode built a software layer called EarnOS that pays users for everyday phone activity — browsing, music, games, charging. Brands pay Mode for the engagement. Mode shares the revenue with users.

It's a closed loop. And it works without Google's ad infrastructure.

$115M+ in revenue. $11.8M EBITDA in 2025. 490M+ users across 170 countries. Monthly profitability since April 2025.

Deloitte ranked them the #1 fastest-growing software company in North America. 32,481% over three years.

They've reserved $MODE on the Nasdaq.

Pre-IPO shares are still $0.50. Up to 20% bonus for early investors.*

The ad economy is getting reshuffled. Mode is already positioned on the other side of it.

Get the details here.

The majority of states now allow medical marijuana, with many also permitting recreational use. This has created a system where federal classification has lagged behind actual practice. While reclassification doesn’t completely bridge this gap, it does move federal policy in a direction that is closer to how marijuana is already being used.

The decision has also revealed some divisions within the Republican Party. Some lawmakers in Washington believe that rescheduling could lead to more normalization and increased access, particularly amongst younger Americans, while others support it as a limited step focused on medical research and patient care.

How It Affects You

The announcement has big ramifications for how treatment is evaluated for patients who are considering medical marijuana as a remedy. Reclassifying marijuana out of the most restrictive category removes barriers for clinical research, which has been limited for decades by federal oversight.

This could lead to more controlled trials, better funding, and better-defined medical use cases, especially for conditions like PTSD and chronic pain. However, it will not change how patients obtain it, as that will still depend on state programs with inconsistent standards and oversight. Reclassification can also reduce many compliance risks and make research partnerships, finance, and wider institutional involvement more viable, effectively changing how providers and companies operate behind the scenes.

This sets a baseline for where federal policy could go next. Once marijuana is formally recognized as having medical use, it becomes easier for regulators and lawmakers to justify further changes, whether that’s expanding approved treatments, adjusting banking rules, or revisiting classification altogether.

It also gives larger institutions, such as pharmaceutical companies and hospital systems, a clearer path to get involved without the same legal risks. However, if the process stalls at reclassification, the system could remain split, with federal law still lagging behind widespread state use. The significance of this move depends on whether it becomes a stepping stone to wider reform or just a limited update focused on research.

*Disclaimer: Please read the offering circular and related risks at invest.modemobile.com. This is a paid advertisement for Mode Mobile’s Regulation A+ Offering.

Mode Mobile recently received their ticker reservation with Nasdaq ($MODE), indicating an intent to IPO in the next 24 months. An intent to IPO is no guarantee that an actual IPO will occur.

The Deloitte rankings are based on submitted applications and public company database research, with winners selected based on their fiscal-year revenue growth percentage over a three-year period.

Mode cumulative revenue includes full year revenue of businesses acquired in 2025.

Mode 2025 EBITDA includes full year EBITDA of businesses acquired in 2025